Monitoring the Patient with Retinal Angiopathy Associated with Hereditary Transthyretin Amyloidosis: Current Perspectives

References

• Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641–2654. doi:10.1016/S0140-6736(15)01274-X
   PubMed Web of Science ®Google Scholar
• Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829–837. doi:10.1002/MUS.26034
   PubMed Web of Science ®Google Scholar
• Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (North of Portugal). Am J Med Genet - Neuropsychiatr Genet. 1995;60(6):512–521. doi:10.1002/ajmg.1320600606
   Web of Science ®Google Scholar
• Conceicão I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve. 2007;35(1):116–118. doi:10.1002/MUS.20644
   PubMed Web of Science ®Google Scholar
• Beirão JM, Malheiro J, Lemos C, Beiraõ I, Costa P, Torres P. Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases. Amyloid. 2015;22(2):117–122. doi:10.3109/13506129.2015.1015678
   PubMed Web of Science ®Google Scholar
• Ando E, Ando Y, Okamura R, Uchino M, Ando M, Negi A. Ocular manifestations of familial amyloidotic polyneuropathy type I: long term follow up. Br J Ophthalmol. 1997;81(4):295–298. doi:10.1136/bjo.81.4.295
   PubMed Web of Science ®Google Scholar
• Latasiewicz M, Sala-Puigdollers A, Gonzalez-Ventosa A, Milla E, Adan Civera A. Multimodal retinal imaging of familial amyloid polyneuropathy. Ophthalmic Genet. 2019;40(5):407–420. doi:10.1080/13816810.2019.1666413
   PubMed Web of Science ®Google Scholar
• Marques JH, Coelho J, Malheiro J, Pessoa B, Beirão JM. Subclinical retinal angiopathy associated with hereditary transthyretin amyloidosis–assessed with optical coherence tomography angiography. Amyloid. 2021;28(1):66–71. doi:10.1080/13506129.2020.1827381
   PubMed Web of Science ®Google Scholar
• Marta A, Marques JH, Ferreira A, Coelho J, Beirão JM. Choroidal involvement in hereditary transthyretin amyloidosis patients. Retina. 2022;42(4):775–781. doi:10.1097/IAE.0000000000003378
   PubMed Web of Science ®Google Scholar
• Rousseau A, Terrada C, Touhami S, et al. Angiographic signatures of the predominant form of familial transthyretin amyloidosis (Val30Met Mutation). Am J Ophthalmol. 2018;192:169–177. doi:10.1016/j.ajo.2018.05.023
   PubMed Web of Science ®Google Scholar
• Reynolds MM, Veverka KK, Gertz MA, et al. Ocular manifestations of familial transthyretin amyloidosis. Am J Ophthalmol. 2017;183:156–162. doi:10.1016/J.AJO.2017.09.001
   PubMed Web of Science ®Google Scholar
• Patil NS, Iqbal MM, Bursztyn LLCD. Conjunctival lymphangiectasia and retinal angiopathy in hereditary transthyretin amyloidosis. Int J Retin Vitr. 2022;8(1). doi:10.1186/S40942-021-00357-X
   PubMedGoogle Scholar
• Dias-Santos A, Ferreira J, Cunha JP. Macular and optic disc edema and retinal vascular leakage in familial amyloid polyneuropathy with a transthyretin Val30Met mutation: a case report. J Med Case Rep. 2014;8(1). doi:10.1186/1752-1947-8-327
   PubMedGoogle Scholar
• Veronese C, Marcheggiani EB, Tassi F, Gallelli I, Armstrong GW, Ciardella AP. Fundus autofluorescence imaging in hereditary ATTR amyloidosis with ocular involvement. Amyloid. 2013;20(4):269–271. doi:10.3109/13506129.2013.823082
   PubMed Web of Science ®Google Scholar
• Falls HF, Jackson J, Carey JH, Rukavina JG, Block WD. Ocular manifestations of hereditary primary systemic amyloidosis. AMA Arch Ophthalmol. 1955;54(5):660–664. doi:10.1001/ARCHOPHT.1955.00930020666004
   PubMedGoogle Scholar
• Tasiopoulou A, Ong D, Lightman S. Characteristic needle-shaped pattern seen on OCT in a patient with ocular amyloidosis. Ophthalmol Retin. 2021;5(1):99–101. doi:10.1016/J.ORET.2020.07.010
   PubMedGoogle Scholar
• Zou X, Dong F, Zhang S, Tian R, Sui R. Transthyretin Ala36Pro mutation in a Chinese pedigree of familial transthyretin amyloidosis with elevated vitreous and serum vascular endothelial growth factor. Exp Eye Res. 2013;110:44–49. doi:10.1016/J.EXER.2013.02.005
   PubMed Web of Science ®Google Scholar
• Sandhu R, Westcott M, Pavesio C, et al. Retinal microangiopathy as an initial manifestation of familial amyloid cardiomyopathy associated with transthyretin e89k mutation. Retin Cases Brief Rep. 2013;7(3):271–275. doi:10.1097/ICB.0B013E31828EEFA2
   PubMedGoogle Scholar
• Lv W, Chen J, Chen W, Hou P, Pang CP, Chen H. Multimodal retinal imaging in a Chinese kindred with familial amyloid polyneuropathy secondary to transthyretin Ile107Met mutation. Eye. 2014;28(4):452–458. doi:10.1038/EYE.2014.10
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang B, Jin X, et al. Ophthalmic manifestations in a Chinese family with familial amyloid polyneuropathy due to a TTR Gly83Arg mutation. Eye. 2014;28(1):26–33. doi:10.1038/EYE.2013.217
   PubMed Web of Science ®Google Scholar
• Noble KG. Bilateral multifocal retinal arteriolar sheathing as the only ocular finding in hereditary amyloidosis. Am J Ophthalmol. 1998;125(1):111–113. doi:10.1016/S0002-9394(99)80249-9
   PubMed Web of Science ®Google Scholar
• Kakihara S, Hirano T, Kitahara J, et al. Ocular angiographic features in Japanese patients with val30met hereditary transthyretin amyloidosis. Retina. 2022;42(1):210–215. doi:10.1097/IAE.0000000000003291
   PubMed Web of Science ®Google Scholar
• Kawaji T, Ando Y, Nakamura M, et al. Ocular amyloid angiopathy associated with familial amyloidotic polyneuropathy caused by amyloidogenic transthyretin Y114C. Ophthalmology. 2005;112(12):2212.e1–2212.e8. doi:10.1016/j.ophtha.2005.05.028
   PubMed Web of Science ®Google Scholar
• Bunod R, Adams D, Cauquil C, et al. Conjunctival lymphangiectasia as a biomarker of severe systemic disease in Ser77Tyr hereditary transthyretin amyloidosis. Br J Ophthalmol. 2020;104(10):1363–1367. doi:10.1136/BJOPHTHALMOL-2019-315381
   PubMed Web of Science ®Google Scholar
• Kakihara S, Hirano T, Matsuda Y, et al. Deposits on retinal surface seen on OCT in ocular amyloidosis. Ophthalmol Retin. 2021;5(10):1005–1008. doi:10.1016/J.ORET.2020.12.028
   PubMedGoogle Scholar
• Choi KJ, Son KY, Kang SW, et al. Ocular manifestations of asp38ala and thr59lys familial transthyretin amyloidosis. Retina. 2022;42(2):396–403. doi:10.1097/IAE.0000000000003296
   PubMed Web of Science ®Google Scholar
• Paton D, Duke JR. Primary familial amyloidosis. Am J Ophthalmol. 1966;61(4):736–747. doi:10.1016/0002-9394(66)91211-6
   PubMed Web of Science ®Google Scholar
• Rowczenio D. Mutations in hereditary amyloidosis. Available from: http://amyloidosismutations.com/mut-attr.php. Accessed April 17, 2022.
   Google Scholar
• O’Hearn TM, Fawzi A, He S, Rao NA, Lim JI. Early onset vitreous amyloidosis in familial amyloidotic polyneuropathy with a transthyretin Glu54Gly mutation is associated with elevated vitreous VEGF. Br J Ophthalmol. 2007;91(12):1607–1609. doi:10.1136/BJO.2007.119495
   PubMed Web of Science ®Google Scholar
• Beirão NM, Miranda V, Beirão I, Costa PP, Torres P. The use of intravitreal ranibizumab to treat neovascular glaucoma because of retinal amyloid angiopathy in familial amyloidosis transthyretin v30m related. Retin Cases Brief Rep. 2013;7(1):114–116. doi:10.1097/ICB.0B013E3182681259
   PubMedGoogle Scholar
• Dunlop AAS, Graham SL. Familial amyloidotic polyneuropathy presenting with rubeotic glaucoma. Clin Exp Ophthalmol. 2002;30(4):300–302. doi:10.1046/j.1442-9071.2002.00539.x
   PubMed Web of Science ®Google Scholar
• Kawaji T, Ando Y, Hara R, Tanihara H. Novel therapy for transthyretin-related ocular amyloidosis: a pilot study of retinal laser photocoagulation. Ophthalmology. 2010;117(3):552–555. doi:10.1016/J.OPHTHA.2009.07.042
   PubMed Web of Science ®Google Scholar
• Buxbaum JN, Brannagan T, Buades-Reinés J, et al. Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis. Amyloid. 2019;26(1):10–14. doi:10.1080/13506129.2018.1554563
   PubMed Web of Science ®Google Scholar
• Casal I, Monteiro S, Beirão JM. Tafamidis in hereditary ATTR amyloidosis–our experience on monitoring the ocular manifestations. Amyloid. 2016;23(4):262–263. doi:10.1080/13506129.2016.1236332
   PubMed Web of Science ®Google Scholar
• Marques JH, Coelho J, Menéres MJ, Beirão JM. Progressive vitreous deposits during treatment with inotersen for hereditary ATTR amyloidosis. Amyloid. 2021;28(4):275–276. doi:10.1080/13506129.2021.1975673
   PubMed Web of Science ®Google Scholar
• Chen JJ, Kalevar A, Vora RA, et al. Transthyretin V30M familial amyloidosis presenting as isolated retinal angiopathy. Retin Cases Brief Rep. 2018;12:S76–S80. doi:10.1097/ICB.0000000000000642
   PubMedGoogle Scholar